Outcome in phospholamban R14del carriers results of a large multicentre cohort study

Circulation: Cardiovascular Genetics

Volumn 7, Issue 4, 2014, Pages 455-465

  Van Rijsingen, Ingrid A W ^a   Van Der Zwaag, Paul A ^b   Groeneweg, Judith A ^c,d   Nannenberg, Eline A ^a   Jongbloed, Jan D H ^b   Zwinderman, Aeilko H ^a   Pinto, Yigal M ^a,c   Lekanne Dit Deprez, Ronald H ^a   Post, Jan G ^d   Tan, Hanno L ^a   De Boer, Rudolf A ^b   Hauer, Richard N W ^c,d   Christiaans, Imke ^a   Van Den Berg, Maarten P ^b   Van Tintelen, J Peter ^b   Wilde, Arthur A M ^a,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Arrhythmias cardiac; Arrhythmogenic right ventricular dysplasia cardiomyopathy; Cardiomyopathy dilated; Genetics; Mortality; Phospholamban; Risk factors

Indexed keywords

PHOSPHOLAMBAN; CALCIUM BINDING PROTEIN;

ADULT; AGE; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE DELETION; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROGNOSIS; STANDARDIZED MORTALITY RATIO; AGED; CLINICAL TRIAL; COHORT ANALYSIS; ELECTROCARDIOGRAPHY; GENETICS; HEART RIGHT VENTRICLE DYSPLASIA; LIVER FAILURE; METABOLISM; MORTALITY; MULTICENTER STUDY; PATHOLOGY; QUESTIONNAIRE; RISK FACTOR; SURVIVAL;

ADULT; AGE FACTORS; AGED; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CALCIUM-BINDING PROTEINS; COHORT STUDIES; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GENE DELETION; HUMANS; LIVER FAILURE; MALE; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84914176677     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.113.000374     Document Type: Article

References (36)

1. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, et al. A molecular basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin heavy chain gene missense mutation. Cell. 1990;62:999-1006
2. Jacoby D, McKenna WJ. Genetics of inherited cardiomyopathy. Eur Heart J. 2012;33:296-304
3. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011;13:1077-1109
4. Raju H, Alberg C, Sagoo GS, Burton H, Behr ER. Inherited cardiomyopathies. BMJ. 2011;343:d6966
5. MacLennan DH, Kranias EG. Phospholamban: A crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003;4:566-577
6. Posch MG, Perrot A, Geier C, Boldt LH, Schmidt G, Lehmkuhl HB, et al. Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes. Heart Rhythm. 2009;6:480-486
7. Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci U S A. 2006;103:1388-1393
8. DeWitt MM, MacLeod HM, Soliven B, McNally EM. Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1396-1398
9. Van Der Zwaag PA, van Rijsingen IA, Asimaki A, Jongbloed JD, van Veldhuisen DJ, Wiesfeld AC, et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail. 2012;14:1199-1207
10. Groeneweg JA, Van Der Zwaag PA, Jongbloed JD, Cox MG, Vreeker A, de Boer RA, et al. Left-dominant arrhythmogenic cardiomyopathy in a large family: Associated desmosomal or nondesmosomal genotype? Heart Rhythm. 2013;10:548-559
11. Van Der Zwaag PA, van Rijsingen IA, de Ruiter R, Nannenberg EA, Groeneweg JA, Post JG, et al. Recurrent and founder mutations in the Netherlands-Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy. Neth Heart J. 2013;21:286-293
12. Groeneweg JA, Van Der Zwaag PA, Olde Nordkamp LR, Bikker H, Jongbloed JD, Jongbloed R, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy according to revised 2010 task force criteria with inclusion of non-desmosomal phospholamban mutation carriers. Am J Cardiol. 2013;112:1197-1206
13. Sen-Chowdhry S, Syrris P, Ward D, Asimaki A, Sevdalis E, McKenna WJ. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation. 2007;115:1710-1720
14. Mestroni L, Maisch B, McKenna WJ, Schwartz K, Charron P, Rocco C, et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J. 1999;20:93-102
15. Caforio AL, Mahon NG, Baig MK, Tona F, Murphy RT, Elliott PM, McKenna WJ. Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation. 2007;115:76-83
16. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J. 2010;31:806-814
17. Robert O. Bonow DLM, Zipes DP, Libby P. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 6th ed. Philadelphia: W.B. Saunders Company; 2001
18. Ronald J. Prineas RSC, Zhu-ming Z. The Minnesota Code Manual of Electrocardiographic Findings. 2nd ed. London: Springer; 2010
19. Gimeno JR, Tomé-Esteban M, Lofiego C, Hurtado J, Pantazis A, Mist B, et al. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J. 2009;30:2599-2605
20. Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J Am Coll Cardiol. 2005;45:1364-1367
21. Nannenberg EA, Michels M, Christiaans I, Majoor-Krakauer D, Hoedemaekers YM, van Tintelen JP, et al. Mortality risk of untreated myosinbinding protein C-related hypertrophic cardiomyopathy: insight into the natural history. J Am Coll Cardiol. 2011;58:2406-2414
22. Nannenberg EA, Sijbrands EJ, Dijksman LM, Alders M, van Tintelen JP, Birnie M, et al. Mortality of inherited arrhythmia syndromes: insight into their natural history. Circ Cardiovasc Genet. 2012;5:183-189
23. Graphics Sefsca. Software Environment for Statistical Computing and Graphics
24. Lipsitz SR, Dear KB, Zhao L. Jackknife estimators of variance for parameter estimates from estimating equations with applications to clustered survival data. Biometrics. 1994;50:842-846
25. Wei L, Lin, DY, Weissfeld, L. Regression analysis of multivariate incomplete failure time data by modelling marginal distributions. J Am Stat Assoc. 1989;84:9
26. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e385-484
27. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol. 2003;42:1959-1963
28. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52:1250-1260
29. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-Associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62:1290-1297
30. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: A position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270-276
31. Hulot JS, Jouven X, Empana JP, Frank R, Fontaine G. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2004;110:1879-1884
32. Quarta G, Syrris P, Ashworth M, Jenkins S, Zuborne Alapi K, Morgan J, et al. Mutations in the Lamin A/C gene mimic arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2012;33:1128-1136
33. van Tintelen JP, Van Gelder IC, Asimaki A, Suurmeijer AJ, Wiesfeld AC, Jongbloed JD, et al. Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. Heart Rhythm. 2009;6:1574-1583
34. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, et al. Right ventricular dysplasia: A report of 24 adult cases. Circulation. 1982;65:384-398
35. Kim C, Wong J, Wen J, Wang S, Wang C, Spiering S, et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature. 2013;494:105-110
36. van Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, Van Der Kooi AJ, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol. 2012;59:493-500.